Skip to main content

BREYNA

ICSLABA MDI

Budesonide / Formoterol fumarate dihydrate · Viatris (Mylan)

Clinical Reference · Data reviewed June 2026

Active Medication & Mechanism

  • Budesonide ICS
    80 mcg or 160 mcg per actuation

    Corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. Inhibits inflammatory cells and mediators involved in airway inflammation.

  • Formoterol fumarate dihydrate LABA
    4.5 mcg per actuation

    Long-acting beta2-adrenergic agonist with rapid onset. Relaxes bronchial smooth muscle by stimulating beta2-receptors.

FDA-Approved Dosing — Strength × Indication

80/4.5 mcg 2 inhalations twice daily → 320/18 mcg
Asthma FDA Approved
Authorized generic of Symbicort. For patients whose asthma is not adequately controlled on a long-term asthma control medication.
COPD Not Approved
The 80/4.5 mcg strength is NOT indicated for COPD. Only 160/4.5 is approved for COPD.
160/4.5 mcg 2 inhalations twice daily → 640/18 mcg
Asthma FDA Approved
Higher strength for patients not controlled on medium-dose ICS.
COPD FDA Approved
Maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and emphysema.

All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling

Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.

Related Inhalers

For educational reference by healthcare professionals. Not medical advice and not for use in clinical decision-making. This workspace is not a substitute for clinical judgement, prescribing information, or product monographs — always verify doses and indications against the most current labelling. If you are a patient, do not use this site to make medication decisions — speak with your clinician.

Device images are original illustrations for identification aid only — actual devices and packaging may differ. This site is not affiliated with or endorsed by any pharmaceutical manufacturer. Clinical data last reviewed: June 2026.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved